Overview
Converge Bio, based in Tel Aviv-Yafo, Israel, has raised $25M in a Series A round on Jan 13, 2026, with participation from Bessemer Venture Partners. The company the Generative AI Lab for the Life Sciences. The round will be used to accelerate product development, expand the team, and scale go-to-market operations.
Operating in the biotechnology research sector, Converge Bio is positioned to capitalize on growing demand for innovative solutions in this space. The company was founded in 2024 by Dov Gertz. Dov brings deep domain expertise and a track record of execution that attracted investor confidence in this round. With fresh capital, the company is expected to invest heavily in R&D and talent acquisition, signaling a period of aggressive growth ahead.
Market Outlook
This funding positions Converge Bio as one to watch in the biotechnology research landscape. As the company scales, it will likely become an increasingly attractive partner — and customer — for B2B vendors looking to sell into well-funded, growth-stage companies. The post-raise window of 60-90 days is typically when startups are most receptive to new tools, services, and partnerships.
Why contact Converge Bio now
Converge Bio just closed $25M in Series A funding — which means they're actively scaling their team, upgrading their tech stack, and looking for vendors who can help them move fast. Companies at this stage typically make purchasing decisions within 60-90 days of closing a round. If you sell to biotechnology research companies, this is your window to reach out before competitors do.
Founders & Contacts
Investors
Company Facts
| Company | Converge Bio |
| Amount Raised | $25M |
| Funding Round | Series A |
| Date Raised | Jan 13, 2026 |
| Founded | 2024 |
| Industry | Biotechnology Research |
| Founders | Dov Gertz |
| HQ Location | Tel Aviv-Yafo, Israel |
Get Verified Founder Emails
Access verified email addresses and contact details for Converge Bio's founders and thousands of other funded startups.
Start Free Trial